Charles Riv­er works on rare dis­ease gene ther­a­py; Emer­gent gets $75M for an­thrax vac­cine; Eu­roAPI hires new COO 

Wel­come to End­points News’ man­u­fac­tur­ing news briefs, where we bring you es­sen­tial up­dates on new builds, col­lab­o­ra­tions, re­calls and more.

Charles Riv­er and the Aus­tralian non­prof­it Ge­net­ic Cures for Kids part­nered on Tues­day to de­vel­op and man­u­fac­ture a gene ther­a­py for the hered­i­tary neu­rode­gen­er­a­tive dis­ease called spas­tic para­ple­gia type 56 (SPG56) by us­ing Charles Riv­er’s plas­mid pro­duc­tion plat­form eX­pDNA. SPG56 is a rare dis­ease af­fect­ing chil­dren, leav­ing them un­able to walk and talk in­de­pen­dent­ly.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER